Critics complain that pharmaceutical research budgets emphasize non$-$debilitating conditions common in developed countries rather than life$-$threatening diseases common in developing countries. People answering this criticism have contended that $q,$

A$.$ by being located almost entirely in developed countries, pharmaceutical companies lack access to locations where they can study diseases such as malaria and sleeping sickness

B$.$ pharmaceutical companies cannot recoup expenses for research on some of the developing country problems, so governmental research centers and nonprofit foundations should handle this research

C$.$ correction of developed country conditions, such as balding, are necessary to stimulate developing country innovations that push global economic growth

D$.$ very small portions of research budgets actually target these non$-$debilitating conditions